<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Digital Diagnostics</journal-id><journal-title-group><journal-title xml:lang="en">Digital Diagnostics</journal-title><trans-title-group xml:lang="ru"><trans-title>Digital Diagnostics</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Digital Diagnostics</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2712-8490</issn><issn publication-format="electronic">2712-8962</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">677671</article-id><article-id pub-id-type="doi">10.17816/DD677671</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>科学评论</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">METABOLIC PROFILE OF LIVER TUMORS USING MAGNETIC RESONANCE SPECTROSCOPY DATA</article-title><trans-title-group xml:lang="ru"><trans-title>МЕТАБОЛИЧЕСКИЙ ПРОФИЛЬ ОПУХОЛЕЙ ПЕЧЕНИ ПО ДАННЫМ МАГНИТНО-РЕЗОНАНСНОЙ СПЕКТРОСКОПИИ</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2232-8264</contrib-id><name-alternatives><name xml:lang="en"><surname>Djuraeva</surname><given-names>Nigora M.</given-names></name><name xml:lang="ru"><surname>Джураева</surname><given-names>Нигора Мухсумовна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>DSc, Head of the Department of MRI and CT Diagnostics, Republican Specialized Scientific and Practical Medical Center of Surgery named after academician V. Vakhidov</p></bio><bio xml:lang="ru"><p>д.м.н., заведующая отделением МР и КТ диагностики Республиканского специализированного научно-практического медицинского центра хирургии им. академика В. Вахидова</p></bio><email>njuraewa@yandex.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0002-0042-3399</contrib-id><contrib-id contrib-id-type="spin">1317-7662</contrib-id><name-alternatives><name xml:lang="en"><surname>Khursanova</surname><given-names>Dilnura Kh.</given-names></name><name xml:lang="ru"><surname>Хурсанова</surname><given-names>Дильнура Хошимовна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>PhD candidate, Junior Research Fellow at the Department of MRI and CT Diagnostics, Republican Specialized Scientific and Practical Medical Center of Surgery named after Academician Vakhidov</p></bio><bio xml:lang="ru"><p>Базовый докторант (аспирант), младший научный сотрудник отделения МР и КТ диагностики Республиканского специализированного научно-практического медицинского центра хирургии им. академика В. Вахидова</p></bio><email>xursanovadilnura@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1785-8890</contrib-id><name-alternatives><name xml:lang="en"><surname>Egamberdiev</surname><given-names>Dilshod M.</given-names></name><name xml:lang="ru"><surname>Эгамбердиев</surname><given-names>Дилшод Махмудович</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="UZ">Uzbekistan</country></address><bio xml:lang="en"><p>DSc, Oncologist at the Department of Abdominal Oncologic Surgery, Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology</p></bio><bio xml:lang="ru"><p>д.м.н., врач-онколог отделения абдоминальной онкохирургии Республиканского специализированного научно-практического медицинского центра онкологии и радиологии</p></bio><email>eclipse1.15@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Republican Specialized Scientific and Practical Medical Center of Surgery named after academician V. Vakhidov</institution></aff><aff><institution xml:lang="ru">Республиканский Специализированный Научно-Практический Медицинский Центр Хирургии им. акад. В. Вахидова</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology</institution></aff><aff><institution xml:lang="ru">Республиканский Специализированный Научно-практический Медицинский Центр Онкологии и Радиологии</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2026-06-15" publication-format="electronic"><day>15</day><month>06</month><year>2026</year></pub-date><volume>7</volume><issue>2</issue><issue-title xml:lang="ru"/><history><date date-type="received" iso-8601-date="2025-03-24"><day>24</day><month>03</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2026-04-20"><day>20</day><month>04</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; , Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; , Эко-вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; , Eco-Vector</copyright-statement><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-вектор</copyright-holder><copyright-holder xml:lang="zh">Eco-Vector</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://jdigitaldiagnostics.com/DD/article/view/677671">https://jdigitaldiagnostics.com/DD/article/view/677671</self-uri><abstract xml:lang="en"><p>Magnetic Resonance Spectroscopy (MRS) is an important non-invasive method used to analyze metabolic changes in liver tumors. The authors conducted a review of scientific studies on the capabilities and applications of ¹H MRS in diagnosing liver lesions using electronic databases PubMed, Web of Science, and Google Scholar with the following keywords: "Magnetic Resonance Spectroscopy", "¹H MRS", "liver lesion", "MRI", "Choline/Lipid", and "MRS metabolites". The search included studies published from the establishment of each respective database until December 2024. The results of numerous studies have shown that MRS provides valuable data on the metabolic composition of liver tumors, including the detection of specific changes in the choline-to-lipid ratio. This enables accurate differentiation of tumor types and assessment of their malignancy. Thus,<bold> </bold>MRS is a reliable tool for diagnosing liver tumors, improving treatment outcomes, and enhancing early-stage diagnostics. Further research in this field may significantly deepen the understanding of metabolic changes, providing additional insights in challenging clinical cases.</p></abstract><trans-abstract xml:lang="ru"><p>Магнитно-резонансная спектроскопия (МРС) является важным неинвазивным методом, применяемым для анализа метаболических изменений в образованиях печени. Авторами был проведен обзор научных исследований возможностей и способов применения 1 HМРС в диагностировании образований печени в электронных базах данных PubMed, Web of Science, Google Scholar по следующим ключевым словам: «Magnetic Resonance Spectroscopy», «1H MRS», «liver lesion», «MRI», «Choline/Lipid», «MRS metabolites». В поиск вошли научные работы, опубликованные с момента основания соответствующей базы данных до декабря 2024 года. Полученные результаты многочисленных исследований показали, что МРС предоставляет ценные данные о метаболическом составе опухолей печени, включая выявление специфических изменений в соотношении холина и липидов. Это позволяет с высокой точностью дифференцировать типы опухолей и оценить степень их злокачественности. Таким образом, МРС является надежным инструментом для диагностики опухолей печени, позволяющим улучшить результаты лечения и повысить уровень диагностики на ранних стадиях. Дальнейшие исследования в этой области могут существенно углубить понимание метаболических изменений в печени, предоставляя дополнительную информацию в спорных клинических случаях.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>Magnetic Resonance Spectroscopy</kwd><kwd>Liver tumor</kwd><kwd>Metabolism, Cho/Lip</kwd><kwd>Diagnostic Imaging</kwd><kwd>Hepatocellular carcinoma</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>Магнитно-резонансная спектроскопия</kwd><kwd>Образования печени</kwd><kwd>Метаболизм</kwd><kwd>Cho/Lip</kwd><kwd>Диагностическая визуализация</kwd><kwd>Гепатоцеллюлярная карцинома</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Kimberly L, Chan L, Ruhm LA, Henning A. MR spectroscopy and spectroscopic imaging. Adv Magn Reson Technol Appl. 2023:421-448. doi:10.1016/b978-0-323-99898-7.00035-3</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Hajek M, Dezortova M. Introduction to clinical in vivo MR spectroscopy. Eur J Radiol. 2008;67:185-193. doi:10.1016/j.ejrad.2007.12.016</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3.	Barker PB. Clinical MR Spectroscopy: Techniques and Applications. Cambridge, UK: Cambridge University Press; 2010.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4.	Zhu H, Barker PB. MR spectroscopy and spectroscopic imaging of the brain. In: Magnetic Resonance Neuroimaging: Methods and Protocols. Springer; 2011:203-226.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5.	Keeler J. Understanding NMR Spectroscopy. Hoboken, NJ: John Wiley &amp; Sons; 2010.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6.	Henriksen O. In vivo quantitation of metabolite concentrations in the brain by means of proton MRS. NMR Biomed. 1995;8:139-148. doi:10.1002/nbm.1940080302</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7.	Barker PB, Hearshen DO, Boska MD. Single-voxel proton MRS of the human brain at 1.5 T and 3.0 T. Magn Reson Med. 2001;45:765-769. doi:10.1002/mrm.1134</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8.	Iqbal Z, Albuquerque K, Chan KL. Magnetic resonance spectroscopy for cervical cancer: review and potential prognostic applications. Cancers (Basel). 2024;16(11):2141. doi:10.3390/cancers16112141</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9.	Lu M, Wu Y, Xia MM, Zhang Y. The role of metabolic reprogramming in liver cancer and its clinical perspectives. Front Oncol. 2024. doi:10.3389/fonc.2024.1454161</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10.	Yao N, Li W, Xu G, et al. Choline metabolism and its implications in cancer. Front Oncol. 2023. doi:10.3389/fonc.2023.1234887</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11.	Mignion L, Danhier P, Magat J, et al. Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism. Int J Cancer. 2016. doi:10.1002/ijc.29932</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12.	Sonkar K, Ayyappan V, Tressler CM, et al. Focus on the glycerophosphocholine pathway in choline phospholipid metabolism of cancer. NMR Biomed. 2019. doi:10.1002/nbm.4112</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13.	Liu C, Liu D, Wang F, et al. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma. Front Immunol. 2022. doi:10.3389/fimmu.2022.1038927</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14.	Currie E, Schulze A, Zechner R, Walther TC, Farese RV. Cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153-161. doi:10.1016/j.cmet.2013.05.017</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15.	Nascimento J, Mariot C, Vianna DR, et al. Fatty acid synthase as a potential new therapeutic target for cervical cancer. An Acad Bras Cienc. 2022;94:e20210670. doi:10.1590/0001-3765202220210670</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16.	Ping P, Li J, Lei H, Xu X. Fatty acid metabolism: a new therapeutic target for cervical cancer. Front Oncol. 2023;13:1111778. doi:10.3389/fonc.2023.1111778</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17.	Kuo YT, Li CW, Chen CY, et al. In vivo proton magnetic resonance spectroscopy of large focal hepatic lesions and metabolite change of hepatocellular carcinoma before and after transcatheter arterial chemoembolization using 3.0-T MR scanner. J Magn Reson Imaging. 2004;19(5):598-604. doi:10.1002/jmri.20046</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18.	Dong AS, Tian JM, Lu JP, Zuo CJ, Wang L, Wang J. Quantitative proton magnetic resonance spectroscopy of the normal liver and malignant hepatic lesions at 3.0 Tesla. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009;31(2):151-154.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19.	Fischbach F, Schirmer T, Thormann M, et al. Quantitative proton magnetic resonance spectroscopy of the normal liver and malignant hepatic lesions at 3.0 Tesla. Eur Radiol. 2008;18(11):2549-2558. doi:10.1007/s00330-008-1040-8</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20.	Liao R, Zhang D, Li X, et al. A preliminary study on the diagnostic efficacy of proton magnetic resonance spectroscopy at 3.0T in rabbit with VX2 liver tumor. Technol Cancer Res Treat. 2021;20:15330338211036852. doi:10.1177/15330338211036852</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21.	Wang D, Li Y. 1H magnetic resonance spectroscopy predicts hepatocellular carcinoma in a subset of patients with liver cirrhosis: a randomized trial. Medicine. 2015;94(27):e1066. doi:10.1097/md.0000000000001066</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22.	Yang Z, Sun S, Chen Y, Li R. Application of single voxel 1H magnetic resonance spectroscopy in hepatic benign and malignant lesions. Med Sci Monit. 2016;22:5003-5010. doi:10.12659/msm.902177</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23.	Zhang L, Zhao X, Ouyang H, et al. Diagnostic value of 3.0T (1)H MRS with choline-containing compounds ratio (∆CCC) in primary malignant hepatic tumors. Cancer Imaging. 2016;16(1):25. doi:10.1186/s40644-016-0082-4</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24.	Ippolito D, Inchingolo R, Grazioli L, et al. Recent advances in non-invasive magnetic resonance imaging assessment of hepatocellular carcinoma. World J Gastroenterol. 2018;24(23):2413-2425. doi:10.3748/wjg.v24.i23.2413</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25.	Jahangiri A, Orekhov V. Beyond traditional magnetic resonance processing with artificial intelligence. Communications chemistry. 2024;7(1). doi:10.1038/s42004-024-01325-w</mixed-citation></ref></ref-list></back></article>
